

## Preconception Care: Making the Difference for Mother and Baby

Maternal and fetal mortality and morbidity remain a significant global health issue and are still unacceptably high<sup>1,2,3</sup>. Every day in 2020, almost 800 women died from preventable causes related to pregnancy and childbirth, with a global maternal mortality rate of 223 per 100,000 live births. Nearly 95% of all maternal deaths occurred in low and lower middle-income countries and most of these deaths could have been prevented<sup>1</sup>.

Reducing maternal mortality is the first target of the Sustainable Development Goal on health and well-being<sup>4</sup>, aimed at reducing the global average maternal mortality rate to below 70 per 100,000 live births by 2030<sup>1,4</sup>. The second target is that of ending preventable deaths of newborns and children under 5 years of age, with all countries aiming at decreasing neonatal mortality rates to at least as low as 12 per 1,000 live births<sup>4</sup>.

In this context, preconception care plays a pivotal role in prevention. Indeed, in 2013 the World Health Organization (WHO) developed a global consensus on preconception care to reduce maternal and childhood mortality and morbidity, recognizing its contribution to improving maternal-fetal outcomes, in both high- and low-income countries<sup>5</sup>.

Preconception care is defined as “*The provision of biomedical, behavioral, and social health interventions to women and couples before conception occurs. It aims to improve their health status and reduce behaviors and individual and environmental factors that contribute to poor maternal and child health outcomes. Its ultimate aim is to improve maternal and child health, in both the short and long term*”<sup>6</sup>. It involves, as a first step, a comprehensive assessment of those medical, social and lifestyle factors that may affect a woman’s health during pregnancy, as well as that of her child<sup>6</sup>.

It has been estimated that, in the 75 high-burden Countdown Countries, which together account for more than 95% of maternal, neonatal and child deaths, increasing the coverage and quality of several interventions, including preconception care, could avert 71% of neonatal deaths (1.9 million, range: 1.6-2.1 million), 33% of stillbirths (0.82 million, range: 0.60–0.93 million) and 54% of maternal deaths (0.16 million, range 0.14-0.17 million) per year, by 2025<sup>7</sup>.

Indeed, preconception care is part and parcel of the “Well Woman Health Care” vision, aimed at preventing illness and promoting wellness for girls and women across the globe.

### The impact of preconception care on fetal-maternal health and non-communicable diseases (NCDs): short- and long-term effects

The association between preconception care, defined as the receipt of specific healthcare services in the 12 months before conception, and the risk of severe maternal morbidity, including maternal death, was examined among 1,514,759 women in the United States. After adjusting for multiple potential confounders, any preconception care was associated with a modestly decreased risk of severe maternal morbidity (adjusted odds ratio-AOR, 0.97; 95% CI, 0.95–1.00). However, in a subgroup analysis of women with chronic diseases, such as hypertension, diabetes, or chronic

kidney disease, any preconception care was associated with a significant decrease in the odds of severe maternal morbidity (AOR, 0.84; 95% CI, 0.77–0.91)<sup>3</sup>. Preconception disorders, such as cardiovascular or mental diseases, diabetes, obesity, anaemia and HIV infection, when aggravated by pregnancy, can also become indirect causes of maternal mortality<sup>8</sup>. Moreover, these disorders can affect embryonic development with long-term consequences for the next generation perpetrating the intergenerational cycle of NCDs<sup>9</sup>. Therefore, all these disorders should be assessed, managed and followed-up as part of preconception care<sup>10</sup>. For example, in women with pre-gestational diabetes mellitus, preconception care can reduce the risk of perinatal mortality by 54% (relative risk-RR 0.46; 95% CI: 0.30–0.73)<sup>11</sup>. Contraceptive care, as well as gynaecologic examinations, were also associated with a decrease in severe maternal morbidity (AOR, 0.84; 95% CI, 0.75–0.95 and AOR, 0.79; 95% CI, 0.71–0.88, respectively)<sup>3</sup>.

The preconception period, is a unique and opportunistic time in a woman's life when she is motivated to adopt healthy behaviour that may potentially benefit her child, making this time period a critical "window of opportunity" to improve pregnancy outcomes. Improving preconception health can ultimately improve both fetal and maternal outcomes<sup>12</sup>. Promoting health before conception has been reported to have several beneficial effects, including a 39% increase in seeking antenatal care and a 17% (RR 0.83; 95% CI: 0.72-0.95) reduction in neonatal mortality<sup>13</sup>.

Preconception health is a broad concept, which encompasses the management of chronic diseases, including correct nutrition, adequate consumption of folic acid, control of body weight and healthy lifestyles and vaccinations<sup>14</sup>.

However, given that approximately 50% of pregnancies around the globe are unplanned, true preconception health care requires routine access to "Well Woman Health Care" which includes the professional asking, whatever the reason for the visit, one key question: "Are you interested in conceiving this year?". If the answer is no, the woman should be offered contraception advice.

If the answer is yes, then all key factors included in the FIGO preconception care checklist should be addressed, including nutrition and weight management, which are all part of the "Well Woman Health Care" strategy<sup>15</sup>.

Many women often do not see a healthcare professional before pregnancy, therefore the postnatal period also offers an opportunity to advise them on optimal health in preparation for a next pregnancy, should it occur, and for women's long-term health.

## Preconception checklist: key factors to be addressed

### Pre-existing chronic medical conditions

Preconception care in women with chronic medical conditions has been associated with an increased likelihood of adopting healthy behavior, such as, medication adherence, folic acid intake and smoking cessation, having quiescent disease during pregnancy and better pregnancy outcomes including reduced congenital anomalies, obstetric complications, rates of preterm birth and low birth weight (LBW)<sup>10</sup>.

Therefore, preconception care is a must for potentially high-risk women during pregnancy because of pre-existing medical conditions, like metabolic, cardiovascular, neurological, autoimmune and/or endocrine diseases. In such cases, preconception care should focus on attaining disease

quiescence during the periconception period, adjusting medications to those appropriate for pregnancy before conception, as well as, verifying compliance with them. Moreover, general healthy behaviours should be promoted including those aimed at limiting exposure to pollutants and toxic chemicals<sup>10,15</sup>.

## Nutrition

Maternal nutrition at conception affects placental development and function, as well as, fetal genomic imprinting/programming and, consequently, the child's long-term health<sup>16,17</sup>. However, a thorough review of the dietary intakes of nutrients for adolescent girls and women in their reproductive age, in low-income and middle-income countries, reported that dietary deficiencies, such as low iron, vitamin A, iodine, zinc and/or calcium, remain prevalent despite the reduction in underweight mothers<sup>18</sup>. Whilst, in high-income countries, a typical diet that includes a high intake of red meat, refined grains/sugars and high-fat dairy products is also lacking in several important micronutrients, such as magnesium, iodine, calcium and vitamin D<sup>19</sup>.

To address these issues, FIGO developed a simple Nutrition Checklist that includes questions on specific dietary requirements, body mass index (BMI), diet quality and micronutrients. Answering these questions raises awareness, identifies potential risks and collects information that can inform health-promoting conversations between women and their healthcare professionals. The FIGO Nutrition Checklist is available online to download for free at [www.figo.org/news/figo-nutrition-checklist](http://www.figo.org/news/figo-nutrition-checklist). A digital version, which provides individualised feedback based on answers (<https://survey.figo.org/c/kuxayx3e>), is also available. This checklist has been validated for use across many healthcare settings. This allows for wider access through mobile 'phones or other electronic devices, as mobile health technologies offer information that is well-accepted by women and particularly beneficial for those who have low socioeconomic status, a young age, and/or a high BMI<sup>20</sup>.

## Obesity

Obesity is the most common medical condition affecting women of reproductive age. Around half of all women in this age group are either overweight or obese<sup>21</sup>. Excessive obesity increases the risk of NCDs, including type 2 diabetes and cardiovascular disease, which contribute to over 70% of global deaths annually<sup>22</sup>.

Moreover, obese women are at risk of vitamin D deficiency due to the vitamin sequestration in adipose tissue<sup>15</sup>. Obesity is an independent risk factor in pregnancy with a higher chance of having pregnancy-associated hypertension, insulin-dependent gestational diabetes and infants with macrosomia. Excessive gestational weight gain (GWG) and postpartum weight retention (PPWR) may play a significant role in long-term obesity. Having one child doubles the five- and 10-year obesity incidence for women, with many women who gain excessive weight during pregnancy remaining obese permanently<sup>23</sup>. Therefore, excessive GWG and/or PPWR should be considered as they significantly contribute to short- and long-term adverse health outcomes for mother, baby and future pregnancies<sup>24</sup>. Women with a BMI of >30 should be referred to a dietician.

## Underweight

Low maternal weight and BMI at conception or delivery, as well as poor weight gain during pregnancy, are associated with LBW, prematurity and maternal delivery complications<sup>25,26,27,28</sup>.

Micronutrient deficiencies, like low folate, iron and/or vitamin B12, may lead to anaemia and its associated adverse pregnancy outcomes<sup>27</sup>. It is recommended that all women be screened for anaemia in the preconception period<sup>15</sup>. Women with severe underweight should be referred to a dietician.

## Supplementation

### Folic acid

Early use of folic acid prevents neural tube defects (NTDs). Adequate levels of folate in pregnancy, measured as a red blood cell folate concentration above 906 nmol/L, can be difficult to achieve through diet alone, therefore, women of reproductive age should be prescribed folic acid both during the preconception period and throughout pregnancy. NTDs occur due to the neural tube failing to close at approximately 3–4 weeks gestation and may lead to infant mortality or long-term disability<sup>29</sup>. Although the proportion of NTDs that can be prevented by sufficient folate intake has not yet been established, the general consensus is that it is probably about 50–60%<sup>30</sup>.

Randomized control trials have reported significant reductions in the prevalence rates of NTDs with adequate folic acid supplementation<sup>31</sup>. Indeed, in developing countries, the introduction of periconceptional folic acid supplementation has been demonstrated to reduce the incidence of neural tube defects (RR = 0.53; 95% CI = 0.41–0.77; two studies, N = 248,056), whilst iron-folic acid supplementation reduced the rates of anaemia (RR = 0.66, 95% CI = 0.53–0.81; six studies; N = 3,430), particularly when supplemented weekly and in a school setting<sup>32</sup>.

Moreover, a study on over 1.5 million women demonstrated that folic acid supplementation, taken three months before pregnancy, was associated with a significantly lower risk of LBW, miscarriage, stillbirth and neonatal mortality, compared to no use<sup>33</sup>.

The WHO recommends routine daily folic acid dosing for low-risk women at a dose of 0.4 mg per day, starting 3 months before conception<sup>38</sup>. Those at increased risk of NTDs, including women with a BMI of > 30, a history of an NTD in a previous child, epilepsy or anticonvulsant use and/or pre-existing type 2 diabetes, require a higher folic acid dose of 4–5 mg per day<sup>35</sup>.

### Other micronutrients

A significant number of women of reproductive age, especially the youngest, do not meet even the minimum recommended levels of certain nutrients in their diet (known as the reference nutrient intake or RNI), in particular mineral intake. For instance, 77% of women aged 18–25 years were found to have insufficient daily dietary intakes of iodine and 96% of women of reproductive age had daily intakes of iron and folate below the recommended levels for pregnancy<sup>36</sup>.

Preconception supplementation of certain micronutrients is associated with a reduction in several adverse obstetric outcomes, for example calcium and vitamin D supplementation reduces the risk of pre-eclampsia<sup>37</sup>; myoinositol, probiotics and micronutrient supplementation decrease the risk of preterm births (aRR 0.43; 95% CI = 0.22–0.82)<sup>38</sup>. Moreover, preconceptional micronutrient supplementation may influence intellectual development in offspring. In fact, preconception supplementation with multiple micronutrients has been found to improve certain domains of

intellectual functioning in offspring at 6-7 years of age, compared to folic acid alone<sup>39</sup>. Therefore, it is crucial to provide information about micronutrient supplementation during preconception counselling.

## Lifestyle variables

### Tobacco smoking cessation

Tobacco use during pregnancy is associated with adverse pregnancy outcomes, including miscarriage, ectopic pregnancy, preterm delivery, fetal growth restriction, small for gestational age, LBW, placental abruption, stillbirth and neonatal death<sup>40,41,42,43</sup>. Indeed, smoking during pregnancy may cause impaired placental development, leading to a hypoxic environment with reduced provision of oxygen and micronutrients to the fetus<sup>42</sup>.

Stopping smoking is associated with improved pregnancy and child health outcomes, including reductions in the incidence of LBW, preterm birth, intensive care unit admissions, and perinatal mortality<sup>44</sup>.

Therefore, as cigarette smoking is one of the most important modifiable risk factors associated with adverse perinatal outcomes, smoking cessation advice should be given to women before pregnancy.

### Alcohol consumption

Alcohol use during pregnancy is a leading, preventable cause of birth defects and developmental disabilities, with Fetal Alcohol Syndrome (FAS) being one of the most severe outcomes. Other adverse health effects associated with alcohol use in pregnancy include miscarriage, preterm labour, intrauterine growth restriction and stillbirth, which all add morbidity to any potential underlying disability<sup>45,46</sup>. Moreover, consuming alcohol during pregnancy may lead to neuropsychological adverse outcomes in the newborn<sup>45,46</sup>.

However, alcohol use in pregnancy remains common, with a global prevalence of approximately 10%, with rates of use varying depending on the country where the woman resides<sup>47</sup>. As a matter of fact, the global prevalence of FAS in children and youths in the general population has been estimated to be 7.7 per 1,000 population<sup>48</sup>.

Women should be advised to avoid drinking alcohol if they are planning a pregnancy. Currently, literature reports no recommended safe level of alcohol consumption during pregnancy. Therefore, preconception counselling should include addressing this issue prior to pregnancy.

### Substance use

Women are at the greatest risk of developing a substance use disorder in their reproductive years with the highest prevalence rates having been observed in adolescence and early adulthood<sup>49</sup>. The use of illicit drugs in pregnancy is associated with adverse maternal, fetal and child outcomes, including abortion, neonatal abstinence syndrome, placental abruption, intrauterine growth restriction, preterm birth, haemorrhage, as well as fetal and infant mortality. Therefore, women should be advised to discontinue the use of such substances and informed about both short- and long-term risks for themselves and their babies<sup>50</sup>.

## Exposure to toxic environmental chemicals

Links between prenatal exposure to environmental chemicals and adverse health outcomes throughout the life course, including negative impacts on fertility, pregnancy, neurodevelopment and cancer, have been documented<sup>51</sup>.

Some of these chemicals are still widely used, such as solvents, pesticides, phthalates, lead, methyl mercury, polycyclic aromatic hydrocarbons, bisphenol A, per- and polyfluorinated substances. They can be found in households and workplaces, in food, water, air and consumer products. Therefore, FIGO considers preventing exposure to environmental chemicals a priority. This involves giving women timely information on how to avoid or reduce such exposure<sup>51</sup>.

Moreover, the health impacts toxic environmental chemicals have can be exacerbated by climate change<sup>52</sup>. Therefore, some advice on protection against the negative consequences of climate change should also be provided during counseling<sup>53</sup>.

## Physical activity

Establishing a pattern of regular physical activity prior to pregnancy is an important component of healthy pregnancy planning as it has a positive effect on the well-being of the mother and it can contribute to the prevention of adverse maternal-fetal outcomes<sup>54</sup>.

Nevertheless, a pooled analysis of 358 population-based surveys with 1.9 million participants, over 18, shows a global age-standardized prevalence of insufficient physical activity of about 32% in females. The highest prevalence (~43%) of insufficient physical activity has been observed in women from Latin America, the Caribbean, South Asia and high-income Western countries<sup>55</sup>.

Pre-pregnancy risk factors for physical inactivity include: a higher or lower than normal pre-pregnancy BMI body mass index, a lower maternal education level and a history of previous live births<sup>56</sup>. Therefore, a more thorough counselling should be offered to patients with these risk factors. Indeed, the presence/absence of knowledge on healthy behaviours have been shown to be the most commonly assessed enabler/barrier to women's lifestyle behaviour change during the preconception period<sup>57</sup>.

The FIGO Pregnancy and Non-Communicable Diseases Committee and the FIGO Committee for Reproductive Medicine, Endocrinology, and Infertility to support the prevention of NCD risk factors, as well as the American Society for Reproductive Medicine and the American College of Obstetricians and Gynecologists (ACOG), recommend moderate physical activity at least 30 minutes a day, 5 days a week, for a minimum of 150 minutes of moderate exercise per week. These levels of exercise are recommended pre-pregnancy, during pregnancy and postpartum<sup>15,58</sup>, as several studies report that pregnant women generally do not engage in much physical activity<sup>54</sup>. Association with dietary modifications is related to a greater weight loss than exercise alone<sup>15,58</sup>.

Particular attention must be paid to some categories, such as professional female athletes. To date, there is a paucity of evidence as to the effects of their physical activity during pregnancy. A recent systematic review suggests that there are no known significant negative consequences of physical activity for pregnant athletes. This would imply that pregnant women who engage in higher impact activities, including elite and competitive athletes, can approach sports with confidence<sup>59</sup>. On the other hand, the ACOG suggests caution, stating that women performing high levels of physical activity may be at risk of hyperthermia, dehydration and excessive weight loss<sup>58</sup>. These risks need to be discussed with female athletes seeking to become pregnant.

## Vaccines

A pregnant woman and her fetus/newborn are vulnerable to severe infectious diseases. Therefore, determining the immunization status of every woman in her reproductive years is of pivotal importance, whatever the reason for her consulting a healthcare professional. This would make it possible for women to be protected when and if the time comes for a pregnancy.

Vaccination to prevent maternal and perinatal adverse outcomes should be offered against hepatitis B (HBV), human papilloma viruses (HPV), influenza, measles-mumps-rubella (MMR), meningococcal (ACWY and B), varicella, tetanus, diphtheria and pertussis<sup>60,61</sup>.

As there is a theoretical risk to the fetus when the mother is given a live virus vaccine, women should be counselled to avoid becoming pregnant for 28 days after having MMR and/or varicella vaccines. Moreover, women who may get pregnant during the influenza season should be given inactivated or recombinant influenza vaccines<sup>62</sup>.

## Pregnancy intervals

Short Inter-Pregnancy Intervals (IPI < 6 months) are associated with preterm birth, very preterm birth, low birth weight, small for gestational age, offspring death, neonatal intensive care unit admission and congenital abnormalities<sup>63</sup>. IPIs between 6-12 months are also associated with increased rates of preterm birth<sup>64</sup>. Moreover, the length of the IPI is a significant contributor to neonatal morbidity, whatever the gestational age at birth. Indeed, both short (< 12 months) and long (> 24 months) IPIs are independently associated with a higher rate and risk of neonatal morbidity, despite preterm influences, as compared to IPIs of 12 to < 24 months<sup>65</sup>.

These data suggest that a time lapse of 12 to < 24 months is most likely the optimal IPI to minimize perinatal adverse outcomes<sup>65</sup> as well as long-term risks for maternal health including all-cause mortality<sup>66</sup>. Furthermore, the woman's individual characteristics and outcome of any previous birth should also be taken into consideration<sup>67</sup> when counselling on the most adequate IPI and appropriate contraception, aiming at decreasing the risks for both mothers and babies.

## FIGO position on preconception care

Preconception care is pivotal in improving women's health before they conceive to prevent short- and long-term adverse outcomes for both mothers and babies. Indeed, preconception care addresses risk factors and health issues that contribute to maternal and perinatal mortality and morbidity, including pre-existing chronic medical conditions, harmful environmental exposures, infectious diseases, incorrect nutrition, unhealthy lifestyles and inadequate inter-pregnancy intervals.

Therefore, it is of utmost importance for public health services to effectively and appropriately address all preconception health needs. To this aim, preconception care should be provided to all women of childbearing age by healthcare professionals during routine visits, whatever their pregnancy intentions.

FIGO's goal is to draw-up a preconception care Checklist for the medical community, so as to promote adequate and homogeneous preconception care in all countries.

## FIGO commitments

FIGO commits itself to advocating the importance of preconception care and promoting initiatives for its appropriate implementation across all Member Societies.

FIGO will do so by:

- Disseminating and developing resources for healthcare professionals on preconception care
- Influencing all healthcare systems, policymakers and providers to ensure that they are made aware of the impact preconception care has on the short- and long-term health of their populations
- Advocating for supportive capacity building for gynecologists, obstetricians, frontline healthcare providers and childbirth educators
- Providing resources to support data collection and monitoring mechanisms at Institutional and Country levels to assess and monitor existing preconception care practices.

## References

1. World Health Organization. Maternal Mortality. <https://www.who.int/news-room/fact-sheets/detail/maternal-mortality> Accessed July 23, 2023.
2. Geller SE, Koch AR, Garland CE, MacDonald EJ, Storey F, Lawton B. A global view of severe maternal morbidity: moving beyond maternal mortality. *Reprod Health*. 2018; 15(Suppl 1): 98.
3. Dude AM, Schueler K, Schumm LP, Murugesan M, Stulberg DB. Preconception care and severe maternal morbidity in the United States. *Am J Obstet Gynecol MFM*. 2022; 4:100549.
4. Sustainable Development Goals (SDG 3) <https://unric.org/en/sdg-3/> Accessed July 23, 2023.
5. World Health Organization. Preconception care. Report of a regional expert group consultation 6–8 August 2013, New Delhi, India
6. World Health Organization (WHO). Meeting to Develop a Global Consensus on Preconception Care to Reduce Maternal and Childhood Mortality and Morbidity. Geneva: WHO, 2013.
7. Bhutta ZA, Das JK, Bahl R, et al. Can available interventions end preventable deaths in mothers, newborn babies, and stillbirths, and at what cost? *Lancet* 2014; S0140-6736(14)60792-3.
8. Storm F, Agampodi S, Eddleston M, Sørensen JB, Konradsen F, Rheinländer T. Indirect causes of maternal death. *Lancet Glob Health* 2014; 2:e566.
9. Fleming TP, Watkins AJ, Velazquez MA, Mathers JC, Prentice AM, Stephenson J, et al. Origins of lifetime health around the time of conception: causes and consequences. *Lancet* 2018; 391:1842-1852.
10. Nana M, Stannard MT, Nelson-Piercy C, Williamson C. The impact of preconception counselling on maternal and fetal outcomes in women with chronic medical conditions: A systematic review. *Eur J Intern Med*. 2023; 108: 52-59.
11. Wahabi HA, Fayed A, Esmaeil S, Elmorshedy H, Titi MA, Amer YS, et al. Systematic review and meta-analysis of the effectiveness of pre-pregnancy care for women with diabetes for improving maternal and perinatal outcomes. *PLoS One*, 2020; 15(8):e0237571.
12. Moos MK, Dunlop AL, Jack BW, Nelson L, Coonrod DV, Long R, et al. Healthier women, healthier reproductive outcomes: recommendations for the routine care of all women of reproductive age. *Am J Obstet Gynecol*. 2008; 199(Suppl. 2):S280-9.
13. Dean SV, Lassi ZS, Imam AM, Bhutta ZA. Preconception care: closing the gap in the continuum of care to accelerate improvements in maternal, newborn and child health. *Reprod Health*. 2014; 11 Suppl 3:S1.
14. Xaverius PK, Tenkku LE, Salas J. Differences between women at higher and lower risk for an unintended pregnancy. *Womens Health Issues* 2009; 19:306-12.



15. Jacob CM, Killeen SL, McAuliffe FM, Stephenson J, Hod M, Diaz Yamal I, et al. Prevention of noncommunicable diseases by interventions in the preconception period: A FIGO position paper for action by healthcare practitioners. *Int J Gynaecol Obstet.* 2020; 151:6-15.
16. King JC. A Summary of Pathways or Mechanisms Linking Preconception Maternal Nutrition with Birth Outcomes. *J Nutr.* 2016; 146(7):1437S-44S
17. Montagnoli C, Santoro CB, Buzzi T, Bortolus R. Maternal periconceptional nutrition matters. A scoping review of the current literature. *J Matern Fetal Neonatal Med.* 2022; 35:8123-8140.
18. Caulfield LE, Velliot V. Program in Human Nutrition, the Johns Hopkins Bloomberg School of Public Health, for SPRING. Nutrition of Adolescent Girls and Women of Reproductive Age in Low- and Middle-Income Countries: Current Context and Scientific Basis for Moving Forward. Arlington, VA: Strengthening Partnerships, Results, and Innovations in Nutrition Globally (SPRING) project, 2015.
19. Stephenson J, Heslehurst N, Hall J, Schoenaker DAJM, Hutchinson J, Cade JE, et al. Before the beginning: nutrition and lifestyle in the preconception period and its importance for future health. *Lancet* 2018; 391(10132):1830-1841.
20. Killeen SL, Donnellan N, O'Reilly SL, Hanson MA, Rosser ML, Medina VP, et al; FIGO Committee on Impact of Pregnancy on Long-term Health and the FIGO Division of Maternal and Newborn Health. Using FIGO Nutrition Checklist counselling in pregnancy: A review to support healthcare professionals. *Int J Gynaecol Obstet.* 2023;160 Suppl 1:10-21.
21. Obesity in Pregnancy: ACOG Practice Bulletin, Number 230. *Obstet Gynecol.* 2021 Jun 1;137(6):e128-e14a
22. McAuliffe FM, Killeen SL, Jacob CM, et al. Management of prepregnancy, pregnancy, and postpartum obesity from the FIGO Pregnancy and Non-Communicable Diseases Committee: A FIGO (International Federation of Gynecology and Obstetrics) guideline. *Int J Gynecol Obstet.* 2020; 151: 16-36.
23. Davis E, Olson C. Obesity in pregnancy. *Prim Care.* 2009; 36(2):341-56
24. Reed J, Case S, Rijhsinghani A. Maternal obesity: Perinatal implications. *SAGE Open Med.* 2023; 11:20503121231176128.
25. Ehrenberg HM, Dierker L, Milluzzi C, Mercer BM. Low maternal weight, failure to thrive in pregnancy, and adverse pregnancy outcomes. *Am J Obstet Gynecol.* 2003; 189(6):1726-30.
26. Dean SV, Lassi ZS, Imam AM, Bhutta ZA. Preconception care: nutritional risks and interventions. *Reprod Health.* 2014; 11 Suppl 3(Suppl 3):S3.
27. Hanson MA, Bardsley A, De-Regil LM, Moore SE, Oken E, Poston L, Ma RC, et al. The International Federation of Gynecology and Obstetrics (FIGO) recommendations on adolescent, preconception, and maternal nutrition: "Think Nutrition First". *Int J Gynaecol Obstet.* 2015; 131 Suppl 4:S213-53.
28. Nagao T, Fukui S, Ohde S, Yamanaka M. The perinatal outcomes by gestational weight gain range at 30 weeks of gestation among pre-pregnancy underweight women. *J Obstet Gynaecol Res.* 2023; 49(2):635-640.
29. Flores AL, Vellozzi C, Valencia D, Sniezek J. Global Burden of Neural Tube Defects, Risk Factors, and Prevention. *Indian J Community Health.* 2014; 26 (Suppl 1):3-5.
30. Pitkin RM. Folate and neural tube defects. *Am J Clin Nutr.* 2007; 85(1):285S-288S.
31. Crider KS, Qi YP, Yeung LF, Mai CT, Head Zauche L, Wang A, Daniels K, Williams JL. Folic Acid and the Prevention of Birth Defects: 30 Years of Opportunity and Controversies. *Annu Rev Nutr.* 2022; 42:423-452.
32. Lassi ZS, Kedzior SG, Tariq W, Jadoon Y, Das JK, Bhutta ZA. Effects of Preconception Care and Periconception Interventions on Maternal Nutritional Status and Birth Outcomes in Low- and Middle-Income Countries: A Systematic Review. *Nutrients.* 2020; 12(3):606.
33. He Y, Pan A, Hu FB, Ma X. (2016). Folic acid supplementation, birth defects, and adverse pregnancy outcomes in Chinese women: a population-based mega-cohort study. *Lancet*, 2016. 388, S91.
34. WHO. Guideline: Daily iron and folic acid supplementation in pregnant women. Geneva, 2012.
35. Dwyer ER, Fillion KB, MacFarlane AJ, Platt RW, Mehrabadi A. Who should consume high-dose folic acid supplements before and during early pregnancy for the prevention of neural tube defects? *BMJ.* 2022; 377:e067728.

36. Stephenson J, Heslehurst N, Hall J, Schoenaker DAJM, Hutchinson J, Cade JE, et al. Before the beginning: nutrition and lifestyle in the preconception period and its importance for future health. *Lancet* 2018; 391(10132):1830-1841.
37. Gunabalasingam S, De Almeida Lima Slizys D, Quotah O, Magee L, White SL, Rigutto-Farebrother J, et al. Micronutrient supplementation interventions in preconception and pregnant women at increased risk of developing pre-eclampsia: a systematic review and meta-analysis. *Eur J Clin Nutr.* 2023; 77(7):710-730.
38. Godfrey KM, Barton SJ, El-Heis S, Kenealy T, Nield H, Baker PN, et al. Myo-Inositol, Probiotics, and Micronutrient Supplementation From Preconception for Glycemia in Pregnancy: NiPPeR International Multicenter Double-Blind Randomized Controlled Trial. *Diabetes Care* 2021; 44(5):1091-1099.
39. Nguyen PH, Young MF, Tran LM, Khuong LQ, Duong TH, Nguyen HC, et al. Preconception micronutrient supplementation positively affects child intellectual functioning at 6 y of age: A randomized controlled trial in Vietnam. *Am J Clin Nutr.* 2021; 113:1199-1208.
40. Andres RL. Perinatal complications associated with maternal smoking. *Semin Neonatol.* 2005; 5:231-241.
41. Pintican D, Poienar AA, Strilciuc S, Mihiu D. Effects of maternal smoking on human placental vascularization: A systematic review. *Taiwan J Obstet Gynecol.* 2019; 58(4):454-459.
42. Diamanti A, Papadakis S, Schoretsaniti S, Rovina N, Vivilaki V, Gratziou C, Katsaounou PA. Smoking cessation in pregnancy: An update for maternity care practitioners. *Tob Induc Dis.* 2019; 17:57.
43. Avşar TS, McLeod H, Jackson L. Health outcomes of smoking during pregnancy and the postpartum period: an umbrella review. *BMC Pregnancy Childbirth* 2021; 21(1):254.
44. Chamberlain C, O'Mara-Eves A, Porter J, Coleman T, Perlen SM, Thomas J, McKenzie JE. Psychosocial interventions for supporting women to stop smoking in pregnancy. *Cochrane Database Syst Rev.* 2017; 2(2):CD001055.
45. Henderson J, Gray R, Brocklehurst P. Systematic review of effects of low-moderate prenatal alcohol exposure on pregnancy outcome. *BJOG.* 2007; 114: 243–252.
46. Muggli E, Matthews H, Penington A, et al. Association between prenatal alcohol exposure and craniofacial shape of children at 12 months of age. *JAMA Pediatr.* 2017; 171:771–780.
47. Popova S, Lange S, Probst C, Gmel G, Rehm J. Estimation of national, regional, and global prevalence of alcohol use during pregnancy and fetal alcohol syndrome: a systematic review and meta-analysis. *Lancet Glob Health.* 2017; 5:e290–e299.
48. Lange S, Probst C, Gmel G, et al. Global prevalence of fetal alcohol spectrum disorder among children and youth: a systematic review and meta-analysis. *JAMA Pediatr.* 2017; 171: 948–956.
49. Merikangas KR, McClair VL. Epidemiology of substance use disorders. *Hum Genet.* 2012; 131: 779–789.
50. Smid MC, Terplan M. What Obstetrician-Gynecologists Should Know About Substance Use Disorders in the Perinatal Period. *Obstet Gynecol.* 2022; 139:317-337.
51. Di Renzo GC, Conry JA, Blake J, DeFrancesco MS, DeNicola N, Martin JN Jr, McCue KA, Richmond D, Shah A, Sutton P, Woodruff TJ, van der Poel SZ, Giudice LC. International Federation of Gynecology and Obstetrics opinion on reproductive health impacts of exposure to toxic environmental chemicals. *Int J Gynaecol Obstet.* 2015 Dec;131(3):219-25.
52. Giudice LC, Llamas-Clark EF, DeNicola N, Pandipati S, Zlatnik MG, Decena DCD, Woodruff TJ, Conry JA; FIGO Committee on Climate Change and Toxic Environmental Exposures. Climate change, women's health, and the role of obstetricians and gynecologists in leadership. *Int J Gynaecol Obstet.* 2021 Dec;155(3):345-356
53. WSPHSU, Guidance from the Western States Pediatric Environmental Health Specialty Unit, Climate Change and Pregnancy Factsheet, 2022
54. Chan CWH, Au Yeung E, Law BMH. Effectiveness of Physical Activity Interventions on Pregnancy-Related Outcomes among Pregnant Women: A Systematic Review. *Int J Environ Res Public Health* 2019; 16(10):1840.

55. Guthold R, Stevens GA, Riley LM, Bull FC. Worldwide trends in insufficient physical activity from 2001 to 2016: a pooled analysis of 358 population-based surveys with 19 million participants. *Lancet Glob Health* 2018; 6:e1077-e1086.
56. Donahue SM, Zimmerman FJ, Starr JR, Holt VL. Correlates of pre-pregnancy physical inactivity: results from the pregnancy risk assessment monitoring system. *Matern Child Health J*. 2010; 14(2):235-44
57. Kandel P, Lim S, Pirota S, Skouteris H, Moran LJ, Hill B. Enablers and barriers to women's lifestyle behavior change during the preconception period: A systematic review. *Obes Rev*. 2021; 22:e13235.
58. American College of Obstetricians and Gynecologists, and Committee on Gynecologic Practice. "Prenatal counseling: committee opinion No. 762." *Fertil Steril*. 2019; 32-42.
59. Wieloch N, Klostermann A, Kimmich N, Spörri J, Scherr J. Sport and exercise recommendations for pregnant athletes: a systematic scoping review. *BMJ Open Sport Exerc Med*. 2022 Nov 25;8(4):e001395.
60. Benedetto C, Carosso A, Corezzi M, Zotti CM; EBCOG. EBCOG position statement: Vaccination in pregnancy. *Eur J Obstet Gynecol Reprod Biol*. 2019; 240:375-376
61. Amaral E, Money D, Jamieson D, Pasupathy D, Aronoff D, Jacobsson B, Lizcano EIO; FIGO Committee on Infections During Pregnancy. Vaccination during pregnancy: A golden opportunity to embrace. *Int J Gynaecol Obstet*. 2023.
62. [www.cdc.gov](http://www.cdc.gov) Accessed July 23, 2023.
63. Wang Y, Zeng C, Chen Y, Yang L, Tian D, Liu X, Lin Y. Short interpregnancy interval can lead to adverse pregnancy outcomes: A meta-analysis. *Front Med* 2022; 9:922053.
64. Lengyel CS, Ehrlich S, Iams JD, Muglia LJ, De Franco EA. Effect of Modifiable Risk Factors on Preterm Birth: A Population Based-Cohort. *Matern Child Health J* 2017; 21:777-785.
65. DeFranco EA, Seske LM, Greenberg JM, Muglia LJ. Influence of interpregnancy interval on neonatal morbidity. *Am J Obstet Gynecol*. 2015; 212(3):386.e1-9.
66. Weisband YL, Manor O, Friedlander Y, Hochner H, Paltiel O, Calderon-Margalit R. Interpregnancy and interbirth intervals and all-cause, cardiovascular-related and cancer-related maternal mortality: findings from a large population-based cohort study. *J Epidemiol Community Health*. 2020; 74:957-963.
67. Mühlrad H, Björkegren E, Haraldson P, Bohm-Starke N, Kopp Kallner H, Brismar Wendel S. Interpregnancy interval and maternal and neonatal morbidity: a nationwide cohort study. *Sci Rep* 2022; 18;12(1):17402

## About FIGO

FIGO is a professional membership organisation that brings together more than 130 obstetrical and gynaecological associations from all over the world. FIGO's vision is that women of the world achieve the highest possible standards of physical, mental, reproductive and sexual health and wellbeing throughout their lives. Our work to achieve this vision is built on four pillars: education, research implementation, advocacy and capacity building.

FIGO leads on global programme activities, with a particular focus on sub-Saharan Africa and South East Asia. We advocate on a global stage, especially in relation to the Sustainable Development Goals (SDGs) pertaining to reproductive, maternal, newborn, child and adolescent health and wellbeing, and non-communicable diseases (SDG3). We also work to raise the status of women and enable their active participation in achieving their reproductive and sexual rights, including through addressing female-genital mutilation (FGM) and gender-based violence (SDG5).

We also provide education and training for our Member Societies and build capacities of those in low-resource countries through strengthening leadership, translating and disseminating good practice and promoting policy dialogues.

FIGO is in official relations with the World Health Organization and a consultative status with the United Nations.

## About the language we use

Within our documents, we often use the terms 'woman', 'girl' and 'women and girls'. We recognise that not all people who require access to gynaecological and obstetric services identify as a woman or girl. All individuals, regardless of gender identity, must be provided with access to appropriate, inclusive and sensitive services and care.

We also use the term 'family'. When we do, we are referring to a recognised group (perhaps joined by blood, marriage, partnership, cohabitation or adoption) that forms an emotional connection and serves as a unit of society.

FIGO acknowledges that some of the language we use is not naturally inclusive. We are undertaking a thorough review of the words and phrases we use to describe people, health, wellbeing and rights, to demonstrate our commitment to developing and delivering inclusive policies, programmes and services.

**For enquiries** FIGO Communications and Engagement team  
[communications@figo.org](mailto:communications@figo.org) +44 (0) 7383 025 731

## Referencing this statement

International Federation of Gynecology and Obstetrics. *Preconception Care: Making the Difference for Mother and Baby*. 2023. Available from: [www.figo.org/resources/figo-statements/preconception-care-making-difference-mother-and-baby](http://www.figo.org/resources/figo-statements/preconception-care-making-difference-mother-and-baby)